# EDGAR Filing Document

**Accession Number:** 0001638287
**File Stem:** 0001104659-26-003908
**Filing Date:** 2026-1
**Character Count:** 31158
**Document Hash:** c1b564493e77781caa2f5d2614a0e5ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-003908.hdr.sgml**: 20260115

**ACCESSION NUMBER**: 0001104659-26-003908

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260115

**DATE AS OF CHANGE**: 20260115

**EFFECTIVENESS DATE**: 20260115

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MetaVia Inc.
- **CENTRAL INDEX KEY:** 0001638287
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472389984
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292743
- **FILM NUMBER:** 26534841

**BUSINESS ADDRESS:**
- **STREET 1:** 545 CONCORD AVENUE
- **STREET 2:** SUITE 210
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138
- **BUSINESS PHONE:** (857) 702-9600

**MAIL ADDRESS:**
- **STREET 1:** 545 CONCORD AVENUE
- **STREET 2:** SUITE 210
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NeuroBo Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20191231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gemphire Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20150331

**As filed with the Securities and Exchange Commission on January 15, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT<br> UNDER**

**THE SECURITIES ACT OF 1933**

![](tm2528002d20_s1mefimg001.jpg)

**M** **ETAVia INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **47-2389984** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial <br> Classification Code Number) | (IRS Employer<br> Identification Number) |

---

**545 Concord Avenue, Suite 210**

**Cambridge, Massachusetts 02138**

**(857) 702-9600**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Hyung Heon Kim**

**President, Chief Executive Officer and Director**

**545 Concord Avenue, Suite 210**

**Cambridge, Massachusetts 02138**

**(857) 702-9600**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

---

| | |
|:---|:---|
| **Phillip D. Torrence, Esq.<br> Joshua W. Damm, Esq.<br> Honigman LLP<br> 650 Trade Centre Way, Suite 200<br> Kalamazoo, Michigan 49002<br> Tel: (269) 337-7700<br> Fax: (269) 337-7703** | **Michael F. Nertney, Esq.<br> Ellenoff Grossman & Schole LLP<br> 1345 Avenue of the Americas<br> 11th Floor<br> New York, New York 10105<br> Telephone: (212) 370-1300** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this registration statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ⌧

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ⌧ (File No. 333-292581)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ◻

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act.**

**EXPLANATORY NOTE AND INCORPORATION OF**

**CERTAIN INFORMATION BY REFERENCE**

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended ("Securities Act"), MetaVia Inc. ("Registrant") is filing this Registration Statement on Form S-1 (this "Registration Statement") with the Securities and Exchange Commission ("Commission"). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-1 (File No. 333-292581) (the "Prior Registration Statement"), which the Registrant originally filed with the Commission on January 5, 2026, as amended on January 12, 2026, and which the Commission declared effective on January 15, 2026.

The Registrant is filing this Registration Statement for the sole purpose of registering up to an aggregate amount of $6,900,000 in (i) Class A Units (the "Class A Units"), with each Class A Unit consisting of (A) one share of our common stock, par value $0.001 per share (the "common stock"), (B) 1.5 Series C warrants to purchase 1.5 shares of common stock (each, a "Series C Common Warrant"), and (C) 1.5 Series D warrants to purchase 1.5 shares of common stock (each, a "Series D Common Warrant" and, together with the Series C Common Warrants, the "Common Warrants"); (ii) Class B Units (the "Class B Units"), with each Class B Unit consisting of (A) one pre-funded warrant (each, a "pre-funded warrant") to purchase one share of common stock, in lieu of shares of common stock, (B) 1.5 Series C Common Warrants, and (C) 1.5 Series D Common Warrants; and (iii) shares of our common stock issuable upon exercise of pre-funded warrants and Common Warrants. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee Table (Exhibit 107) contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are incorporated by reference into this Registration Statement.

**The required opinions and consents are listed on the Exhibit Index attached hereto and filed herewith.**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [5.1](tm2528002d20_ex5-1.htm) | [Opinion of Honigman LLP.](tm2528002d20_ex5-1.htm) |
| [23.1](tm2528002d20_ex23-1.htm) | [Consent of Independent Registered Public Accounting Firm (BDO USA, P.C.).](tm2528002d20_ex23-1.htm) |
| [23.2](tm2528002d20_ex5-1.htm) | [Consent of Honigman LLP (included in Exhibit 5.1).](tm2528002d20_ex5-1.htm) |
| [24.1](https://www.sec.gov/ix?doc=/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm#POWEROFATTORNEY_705455) | [Power of Attorney (incorporated by reference to Exhibit 24.1 to the Registration Statement on Form S-1 (Registration No. 333-292581)).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm#POWEROFATTORNEY_705455) |
| [107](tm2528002d20_ex-filingfees.htm) | [Filing Fee Table.](tm2528002d20_ex-filingfees.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 15th day of January, 2026.

---

| | |
|:---|:---|
| **MetaVia Inc.** | **MetaVia Inc.** |
| By: | */s/ Hyung Heon Kim* |
|  | Hyung Heon Kim |
|  | President, Chief Executive Officer and Director |

---

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |

---

---

| | | |
|:---|:---|:---|
| */s/ Hyung Heon Kim* | President, Chief Executive Officer and | January 15, 2026 |
| Hyung Heon Kim | Director (Principal Executive Officer) |  |
| */s/ Marshall H. Woodworth* | Chief Financial Officer | January 15, 2026 |
| Marshall H. Woodworth | (Principal Financial Officer and Principal <br> Accounting Officer) |  |

---

---

| | | |
|:---|:---|:---|
| \* |  |  |
| Andrew I. Koven | Chairman of the Board | January 15, 2026 |
| \* |  |  |
| Mark A. Glickman | Director | January 15, 2026 |
| \* |  |  |
| Jason L. Groves | Director | January 15, 2026 |
| \* |  |  |
| Michael Salsbury | Director | January 15, 2026 |
| \* |  |  |
| D. Gordon Strickland | Director | January 15, 2026 |
| \* |  |  |
| James P. Tursi, M.D. | Director | January 15, 2026 |

---

---

| | |
|:---|:---|
| \*By: | /s/ *Hyung Heon Kim* |
|  | Hyung Heon Kim |
|  | Attorney-in-Fact |

---

January 15, 2026

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm2528002d20_ex5-1img001.jpg) | (269) 337-7700 |

---

January 15, 2026

MetaVia Inc.

545 Concord Avenue, Suite 210

Cambridge, Massachusetts 02138

---

| | |
|:---|:---|
| ***Re:*** | ***Registration Statement on Form S-1*** |

---

Ladies and Gentlemen:

We have acted as special counsel to MetaVia Inc., a Delaware corporation (the ***"Company"***), in connection with the offering and sale by the Company of up to $6,900,000 in aggregate sale price of (i) Class A Units, consisting of (A) one share (the ***"Shares"***) of the Company's common stock, par value $0.001 per share (the ***"Common Stock"***), (B) 1.5 Series C Common Warrants to purchase 1.5 shares of Common Stock (the ***"Series C Common Warrants"***), and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of Common Stock (the ***"Series D Common Warrants"***) or (ii) Class B Units, consisting of (A) one pre-funded warrants to purchase one share of Common Stock (the ***"Pre-Funded Warrants***,***"*** and together with the Series C Common Warrants and the Series D Common Warrants, the ***"Warrants"***), (B) 1.5 Series C Common Warrants, and (C) 1.5 Series D Common Warrants, and (iii) shares of Common Stock issuable upon exercise of the Warrants (the ***"Warrant Shares"***). The Shares, the Warrants and the Warrant Shares are included in a registration statement on Form S-1 under the Securities Act of 1933, as amended (the ***"Act"***), filed with the Securities and Exchange Commission (the ***"Commission"***) pursuant to Rule 462(b) of the Act (the ***"Registration Statement"***). The Registration Statement incorporates by reference the Registration Statement on Form S-1 (No. 333-292581) initially filed with the Commission on January 5, 2026, as amended on January 12, 2026, and which was declared effective on January 15, 2026 (the ***"Prior Registration Statement"***), including the prospectus which forms a part of the Prior Registration Statement. The terms "Shares," "Pre-Funded Warrants," "Series C Common Warrants," "Series D Common Warrants," and "Warrant Shares" shall include any additional shares of Common Stock, Pre-Funded Warrants, Series C Common Warrants, Series D Common Warrants and/or Warrant Shares, as applicable, registered by the Company pursuant to Rule 462(b) under the Act in connection with the offering contemplated by the Registration Statement. This opinion letter is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus, other than as expressly stated herein with respect to the issuance of the Shares, the Warrants and the Warrant Shares.

For the purpose of rendering this opinion letter, we examined originals or copies of such documents as we deemed relevant, including the form of underwriting agreement (the ***"Underwriting Agreement"***) filed as an exhibit to the Prior Registration Statement pursuant to which the Shares and the Warrants will be sold. In conducting our examination, we assumed, without investigation, the genuineness of all signatures, the correctness of all certificates, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted as certified or photostatic copies, and the authenticity of the originals of such copies, and the accuracy and completeness of all records made available to us by the Company.

Our opinion is limited solely to matters set forth herein. The law covered by the opinions expressed in this opinion letter is limited to the internal laws of the State of New York and the General Corporation Law of the State of Delaware as currently in effect. We express no opinion as to any other laws. We are not rendering any opinion with respect to federal law, including federal securities laws, or state blue sky securities laws.

With regard to our opinions concerning the Warrants constituting valid and binding obligations of the Company:

&nbsp;&nbsp;&nbsp;&nbsp;A. Our opinions are subject to, and may
 be limited by, (i) applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent
 transfer, voidable transaction, fraudulent conveyance, debtor and creditor, and other laws
 which relate to or affect creditors' rights generally, and (ii) general principles
 of equity (including, without limitation, concepts of materiality, reasonableness, good faith
 and fair dealing) regardless of whether considered in a proceeding in equity or at law.

------

**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**

---

| | |
|:---|:---|
| ![](tm2528002d20_ex5-1img001.jpg) | (269) 337-7700 |

---

&nbsp;&nbsp;&nbsp;&nbsp;B. Our opinions are subject to the qualification
 that the availability of specific performance, an injunction or other equitable remedies
 is subject to the discretion of the court before which the request is brought.

&nbsp;&nbsp;&nbsp;&nbsp;C. We express no opinion as to any provision
 of the Warrants that: (i) provides for liquidated damages, buy-in damages, monetary
 penalties, prepayment or make-whole payments or other economic remedies to the extent such
 provisions may constitute unlawful penalties, (ii) relates to advance waivers of claims,
 defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements,
 statutes of limitations, trial by jury, or procedural rights, (iii) restricts non-written
 modifications and waivers, (iv) provides for the payment of legal and other professional
 fees where such payment is contrary to law or public policy, (v) relates to exclusivity,
 election or accumulation of rights or remedies, (vi) authorizes or validates conclusive
 or discretionary determinations, (vii) provides that provisions of the Warrants are
 severable to the extent an essential part of the agreed exchange is determined to be invalid
 and unenforceable, (viii) any provisions exculpating the purchasers or any of their
 respective representatives from any liability, in each case insofar as such provisions might
 require indemnification or exculpation with respect to any violations of securities laws
 or relating to any litigation by any party determined adversely to any party other than the
 Company.

&nbsp;&nbsp;&nbsp;&nbsp;D. We express no opinion as to whether a
 state court outside of the State of New York or a federal court of the United States would
 give effect to the choice of New York law or jurisdiction provided for in the Warrants.

&nbsp;&nbsp;&nbsp;&nbsp;E. Except to the extent we have expressly
 opined as to such matters with respect to the Company herein, we have assumed (a) that
 the Warrants have been duly authorized, executed and delivered by the parties thereto, (b) that
 the Warrants constitute legally valid and binding obligations of the parties thereto, enforceable
 against each of them in accordance with their respective terms, and (c) that the status
 of the Warrants as legally valid and binding obligations of the parties is not affected by
 any (i) breaches of, or defaults under, agreements or instruments, (ii) violations
 of statutes, rules, regulations or court or governmental orders, or (iii) failures to
 obtain required consents, approvals or authorizations from, or make required registrations,
 declarations or filings with, governmental authorities.

Based on the foregoing and upon our examination of such documents and other matters as we deem relevant, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. When the Shares shall have been
 duly registered on the books of the transfer agent and registrar therefor, and have been
 issued by the Company against payment therefor, in excess of par value, in accordance with,
 and as described in, the Registration Statement and the related prospectus and in the manner
 set forth in the Underwriting Agreement, the Shares will have been duly authorized by all
 necessary corporate action of the Company, and the Shares will be validly issued, fully paid
 and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;2. When the Warrants shall have been duly
 registered on the books of the warrant agent therefor, and have been issued by the Company
 against payment therefor in accordance with, and as described in, the Registration Statement
 and the related prospectus and in the manner set forth in the Underwriting Agreement, the
 Warrants will have been duly authorized by all necessary corporate action of the Company,
 and the Warrants will be legally valid and binding obligations of the Company, enforceable
 against the Company in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;3. When the Warrant Shares shall have been
 duly registered on the books of the transfer agent and registrar therefor, and have been
 issued by the Company upon exercise of the Warrants in accordance with, and as described
 in, the Registration Statement and the related prospectus and in the manner set forth in
 the Warrants, and assuming that at the time of exercise of the Warrants, a sufficient number
 of shares of Common Stock will be authorized, unissued, unreserved and available for issuance
 of the related Warrant Shares, the Warrant Shares will have been duly authorized by all necessary
 corporate action of the Company, and the Warrant Shares will be validly issued, fully paid
 and nonassessable.

------

**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**

---

| | |
|:---|:---|
| ![](tm2528002d20_ex5-1img001.jpg) | (269) 337-7700 |

---

We hereby consent to the filing of this opinion letter as <u>Exhibit 5.1</u> to the Registration Statement and to the reference to our firm under the caption "Legal Matters" in the Registration Statement. In giving such consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations promulgated thereunder by the Commission. This opinion letter is given as of its date based solely on our understanding of facts in existence as of such date, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed in this opinion letter or of any subsequent changes in applicable law.

---

| |
|:---|
| Very truly yours, |
| */s/ Honigman LLP* |
| Honigman LLP |

---

------

**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**

## Exhibit 23.1

**Exhibit 23.1**

<u>Consent of Independent Registered Public Accounting Firm</u>

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 20, 2025, except for the effects of the reverse stock split described in Note 1, as to which the date is January 5, 2026, relating to the consolidated financial statements of MetaVia Inc. (the Company), which are included in the Registration Statement on Form S-1 (No. 333-292581). Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

We also consent to the reference to us under the caption "Experts" in such Registration Statement.

/S/ BDO USA, P.C.

Boston, Massachusetts

January 15, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **MetaVia Inc.**  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation or Carry Forward Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Class A Units, each unit consisting of (i) one share of Common Stock, par value $0.001 per share, (ii) 1.5 Series C Common Warrants to purchase one share of Common Stock, and (iii) 1.5 Series D Common Warrants to purchase one share of Common Stock | 457(o) | $1725000.00 | 0.0001381 | $238.22 |
| Fees to be Paid |  | Equity | Class B Units, each unit consisting of (i) one pre-funded warrant to purchase one share of Common Stock, (ii) 1.5 Series C Common Warrants and (iii) 1.5 Series D Common Warrants | 457(o) | $0.00 | 0.0001381 | $0.00 |
| Fees to be Paid | 2 | Equity | Common Stock included in the Class A Units | 457(o) | $0.00 | 0.0001381 | $0.00 |
| Fees to be Paid | 3 | Equity | Series C Common Warrants included in the Class A and Class B Units | 457(o) | $0.00 | 0.0001381 | $0.00 |
| Fees to be Paid | 4 | Equity | Series D Common Warrants included in the Class A and Class B Units | 457(o) | $0.00 | 0.0001381 | $0.00 |
| Fees to be Paid | 5 | Equity | Pre-Funded Warrants included in the Class B Units | 457(o) | $0.00 | 0.0001381 | $0.00 |
| Fees to be Paid | 6 | Equity | Shares of Common Stock issuable upon exercise of Pre-Funded Warrants, Series C Common Warrants, and Series D Common Warrants | 457(o) | $5175000.00 | 0.0001381 | $714.67 |
| Fees Previously Paid |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | $6900000.00  |  | $952.89  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  |  |  | $952.89  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Estimated solely for the purpose of calculating the registration fee pursuant Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"). Represents only the additional dollar amount of securities being registered and includes the additional dollar amount of securities that the underwriters have the option to purchase to cover over-allotments, if any. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-292581). Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover an indeterminate number of shares of Common Stock that may be issued and resold resulting from stock splits, stock dividends or similar transactions. Includes the price of additional shares of Common Stock, Series C Common Warrants and Series D Common Warrants that may be issued upon exercise of the over-allotment option granted to the underwriters to cover over-allotments, if any. The proposed maximum aggregate offering price of the Class A Units will be reduced on a dollar-for-dollar basis based on the offering price of any Class B Units issued in the offering, and the proposed maximum aggregate offering price of the Class B Units to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Class A Units issued in the offering. Accordingly, the proposed maximum aggregate offering price of the additional Class A Units and Class B Units (including the Common Stock issuable upon exercise of the Pre-Funded Warrants contained in the Class B Units) being registered hereby, if any, is $6,900,000. On January 5, 2025, the Registrant paid a registration fee of $4,764.44 and on January 12, 2025, the Registrant paid a registration fee of $0.01 in connection with the previous filings of the Registration Statement. No additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> See Offering Note 1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>3</sup> See Offering Note 1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>4</sup> See Offering Note 1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>5</sup> See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>6</sup> See Offering Note 1. Each Pre-Funded Warrant is exercisable for one share of Common Stock, and each 1.5 Series C Common Warrant and Series D Common Warrant is exercisable for 1.5 shares of Common Stock. Accordingly, the proposed maximum aggregate offering price of the shares of Common Stock underlying the Pre-Funded Warrants, Series C Common Warrants and Series D Common Warrants $25,875,000.

---

| | |
|:---|:---|
| | |
| **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Securities Previously Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price of Securities Previously Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Form Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **File Number**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Initial Effective Date**  |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---